companiesandmarkets.com

Return to Report | Print

Introgen Therapeutics Inc - Premium Company Profile

http://www.companiesandmarkets.com/Summary-Company-Profile/introgen-therapeutics-inc-premium-company-profile-42821.asp

Report Summary

Introduction

Introgen Therapeutics (Introgen) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer. The company has been successful in developing a strong portfolio of pipeline candidates using its ‘Enabling Technologies’.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Highlights

    The company’s product candidates include includes five clinical-stage product candidates: ADVEXIN and INGN 241 in Phase III clinical trials for head and neck cancer; INGN 225, a therapeutic p53 vaccine, in Phase II clinical development for lung and breast cancer.

    The company's INGN 234, a topical formulation for oral cancer prevention and treatment of oral pre-malignancies, in Phase I clinical development; and INGN 401, a systemic nanoparticle tumor suppressor is in Phase II clinical trials for metastatic lung cancer.

    The company recognizes revenues in the form of contract research fees from other pharmaceutical/biotechnology companies, and grants from academic and government organizations. The company’s total revenues have slightly declined at a CAGR of 0.5% during 2002-2006, almost flat at $1.2 million.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company’s adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Overview 1
    Catalyst 1
    Summary 1
    Table of Contents 2
    Table of figures 3
    Table of tables 4
    Company Structure 5
    Company Overview and Key Facts 5
    Business Description 6
    Landmark Products and Services 6
    Enabling Technologies 6
    History 8
    M&A History 9
    Magnum Therapeutics 9
    Locations and Subsidiaries 10
    Company Financials 11
    Stock Market Performance 11
    P&L 14
    Balance Sheet 17
    Cash Flow 17
    Products & Services 18
    Pipeline Products 18
    In-house Pipeline 18
    Advexin 19
    INGN 241 19
    INGN 225 19
    INGN 401 20
    INGN 234 20
    INGN 402 20
    INGN 403 20
    INGN 007 20
    AC Forecast Product Sales 21
    Competitors and Strategic Business Relationships 23
    Key Competitors 23
    Key Suppliers 23
    Key Clients 25
    Shareholding Structure 26
    Strategy 27
    Company View 27
    Corporate Strategy 29
    SWOT Analysis 31
    Overview 31
    Strengths 32
    Broad proprietary pipeline 32
    Strong intellectual property 32
    Weaknesses 33
    Contract Manufacturing Services 33
    Opportunities 34
    Advexin therapy 34
    Anti-cancer drug market 34
    Threats 35
    Regulatory impact on nature of business 35
    Conflicting obligations 35
    Value Chain Analysis 37
    Overview 37
    Discovery and Product Development 38
    Manufacturing 38
    Scorecard 39
    Overview 39
    Scorecard Analysis 40
    Key Employees 41
    List of Key Employees 41
    Key Employee Biographies 42
    David G Nance 42
    William H Cunningham 42
    S Malcolm Gillis 43
    Peter Barton Hutt 43
    John N Kapoor 44
    Charles E Long 45
    James W Albrecht 45
    C Channing Burke 46
    Max W Talbott 46
    Robert E Sobol 47
    J David Enloe 47
    Kerstin B Menander 48
    David L Parker 48
    Sunil Chada 48
    Financial and Operational Overview 50
    Financial and Operational Overview 50
    APPENDIX 52
    Ask the analyst 52
    Datamonitor consulting 52
    Disclaimer 52
    List of Tables
    Table 1: Introgen - Key Facts 5
    Table 2: Introgen - Other Locations and Subsidiaries 10
    Table 3: Introgen - Year-End Share Price and Market Capitalization, 2002-2006 ($) 11
    Table 4: Introgen - Key Events Impacting Share Price Performance 12
    Table 5: Introgen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 14
    Table 6: Introgen - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 16
    Table 7: Introgen - Balance Sheet, 2002-2006 ($ Mn) 17
    Table 8: Introgen - Cash Flow, 2002-2006 ($ Mn) 17
    Table 9: Introgen - In-house Pipeline Products 18
    Table 10: Introgen - Forecast Sales, 2006-2010 ($ Mn) 21
    Table 11: Introgen - Key Competitors 23
    Table 12: Introgen - Key Suppliers 24
    Table 13: Introgen - Key Clients 25
    Table 14: Introgen - Key Shareholders 26
    Table 15: Introgen - SWOT Analysis Summary 31
    Table 16: Introgen - Value Chain Analysis 37
    Table 17: Introgen - Scorecard 39
    Table 18: Introgen - Key Employees 41
    Table 19: Introgen - Financial and Operational Overview 50
    List of Figures
    Figure 1: Introgen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 15
    Figure 2: Introgen - Key Strategic Revenues, 2006-2010 ($ Mn) 22